News Reader.info

ABSTRACT The association between several Single Nucleotide Polymorphisms (SNPs) within the transcription factor 7-like 2 (_TCF7L2)_ gene and Type 2 Diabetes (T2D) as well as additional 

T2D-related traits is well established. Since alteration in total and regional brain volumes are consistent findings among T2D individuals, we studied the association of four T2D

susceptibility SNPS within _TCF7L2_ (rs7901695, rs7903146, rs11196205, and rs12255372) with volumes of white matter hyperintensities (WMH), gray matter, and regional volumes of amygdala and

hippocampus obtained from structural MRI among 191 T2D elderly Jewish individuals. Under recessive genetic model (controlling for age, sex and intracranial volume), we found that for all

four SNPs, carriers of two copies of the T2D risk allele (homozygous genotype) had significantly smaller amygdalar volume: rs7901695- CC genotype vs. CT + TT genotypes, p = 0.002;

rs7903146-TT vs. TC + CC, p = 0.003; rs11196205- CC vs. CG + GG, p = 0.0003; and rs12255372- TT vs. TG + GG, p = 0.003. Adjusting also for T2D-related covariates, body mass index (BMI), and

ancestry did not change the results substantively (rs7901695, p = 0.003; rs7903146, p = 0.005; rs11196205, p = 0.001; and rs12255372, p = 0.005). Conditional analysis demonstrated that only

rs11196205 was independently associated with amygdalar volume at a significant level. Separate analysis of left and right amygdala revealed stronger results for left amygdalar volume. Taken

together, we report association of _TCF7L2_ SNPs with amygdalar volume among T2D elderly Jewish patients. Further studies in other populations are required to support these findings and

reach more definitive conclusions. SIMILAR CONTENT BEING VIEWED BY OTHERS RISK OF TYPE 2 DIABETES AND _KCNJ11_ GENE POLYMORPHISMS: A NESTED CASE–CONTROL STUDY AND META-ANALYSIS Article Open

access 01 December 2022 A PREVALENT CAVEOLIN-1 GENE RS926198 VARIANT IS ASSOCIATED WITH TYPE 2 DIABETES MELLITUS IN THE THAI POPULATION Article Open access 11 November 2024 ASSOCIATION

BETWEEN TYPE 2 DIABETES AND AMYOTROPHIC LATERAL SCLEROSIS Article Open access 15 February 2022 INTRODUCTION Type 2 diabetes (T2D) is a multifactorial disease, with a complex polygenic

architecture1,2,3. The association of the transcription factor 7-like 2 (_TCF7L2_) gene (chromosome 10q25.2-q25.3) with T2D is one of the most reproducible and robust finding in T2D

genetics, as supported by Genome-wide association studies (GWAS), multiple replication studies and meta-analyses4,5. Several single nucleotide polymorphisms (SNPs) within _TCF7L2_ were

independently associated with T2D susceptibility and related traits (e.g. insulin secretion and blood glucose levels)4,5,6,7,8. The protein encoded by _TCF7L2_ gene is a transcription

factor, involved in the Wnt/beta-catenin signaling pathway, which plays a role in cell proliferation and differentiation9,10. It is related to beta-cells and other pancreatic cells 

functions11,12,13, as well as to the development and function of adipose tissue14. In addition, _TCF7L2_ is expressed in multiple brain regions and characterized by existence of several

alternative splicing variants in different species15,16,17,18. In humans, a unique splice variant was found in the brain, pancreatic islets and gut and therefore named the “neuroendocrine

form“19. SNPs in _TCF7L2_ have been associated with psychiatric disorders, such as schizophrenia and bipolar disorder20,21,22. Individuals with T2D have higher risk for cognitive dysfunction

and dementia than those without T2D23. The most consistent findings in neuroimaging of T2D patients are higher number of infarcts and white matter lesions, as well as general cerebral and

hippocampal atrophy24,25,26. Few studies have found regional atrophy in different brain structures27,28,29, but these results were not consistent. Greater atrophy of the amygdala and

hippocampus had been associated not only with T2D30, but also to high plasma glucose levels within the normal range31. However, the underlying etiology of brain volume differences in T2D is

still unknown. At the genetic level, previous studies in the Israel Diabetes and Cognitive Decline (IDCD) study found that apolipoprotein ε4 (_APOE4_) genotype32 and haptoglobin (Hp) 1–1

genotype33, affect the relationship between neuroimaging phenotypes (White matter hyperintensities [WMHs] and Hippocampal volume, respectively) and glycemic control among T2D patients. We

examined the association of four _TCF7L2_ SNPs (rs7901695, rs7903146, rs11196205, and rs12255372) with WMH, gray matter, and regional volumes of the amygdala and hippocampus obtained from

structural brain magnetic resonance imaging (MRI) in Jewish T2D elderly patients. These SNPs are reported in the literature as robustly associated with T2D4,5. We hypothesized that _TCF7L2_

risk alleles for T2D would be associated with smaller regional brain volume and larger WMH volume among T2D patients. RESULTS DEMOGRAPHIC AND MEDICAL CHARACTERISTICS The final analysis

included 191 T2D individuals, all of them were IDCD participants. The demographic and clinical description of the sample is detailed in Table 1. All participants were both genotyped for the

_TCF7L2_ SNPs (rs7901695, rs7903146, rs11196205, and rs12255372; Table 2) and had brain MRI scans. Genotyping success rate per SNP was 97.38–100% ASSOCIATION OF _TCF7L2_ SNPS WITH THE VOLUME

OF DIFFERENT BRAIN REGIONS We found that two SNPs, rs7903146 and rs7901695 were highly correlated to each other (r2 = 0.94) and can be viewed essentially as a single signal (Table 3). From

the analyzed SNPs, only rs7903146 showed slight deviation form Hardy-Weinberg equilibrium (p = 0.045), but nevertheless we included it in the analysis. The mean volumes of the different

brain regions, according to the four analyzed SNPs and genotypes are described in Table 4. As shown in Table 5, by employing linear regression, we found a significant association in all four

_TCF7L2_ SNPs with amygdalar volume in the recessive genetic model (regression model B - adjusting for sex, age and total intracranial volume [TICV]): rs7901695- CC genotype vs. CT + TT

genotypes, β = −0.21, p = 0.002; rs7903146-TT vs. TC + CC, β = −0.20, p = 0.003; rs11196205- CC vs. CG + GG, β = −0.247, p = 0.0003; and rs12255372- TT vs. TG + GG, β = −0.20, p = 0.003.

These results withstood our threshold for multiple testing correction (p = 0.0042). Controlling also for T2D-related covariates (time in the diabetes registry, mean hemoglobin A1c (HbA1C)

levels and use of T2D medication [yes/no]), body mass index (BMI) and ancestry (regression model B) did not change the results substantively (rs7901695 β = −0.2, p = 0.003; rs7903146 β = 

−0.19, p = 0.005; rs11196205 β = −0.23, p = 0.001; and rs12255372 β = −0.19, p = 0.005), although rs12255372 and rs7903146 no longer withstood the threshold for multiple testing correction 

(Table 5). In all four SNPs, individuals who were homozygous of the T2D risk allele had ~9.5% smaller amygdalar volume compared to the carriers of the non-risk allele (Table 6). Adjusting

also to systolic and diastolic blood pressure values did not change results (regression model C, Supplementary Table 1). In addition, _TCF7L2_ rs11196205 showed a significant association

with amygdalar volume in the additive genetic model (regression model B- p = 0.005; model B- p = 0.008) but did not remain significant when implementing multiple testing correction (Table

5). In order to analyze the potential distinct effect of the four _TCF7L2_ SNPs (under recessive model), we performed a conditional analysis, including a second SNP as a covariate in the

regression model. In the joint analysis of rs11196205 and each of the other three SNP (separately), the association with amygdalar volume was still significant (regression model A- p = 

0.039, p = 0.044, p = 0.033 – controlling for rs7901695, rs7903146 or rs12255372 respectively), or approaching significance (model B- p = 0.08, p = 0.086, p = 0.067 – controlling for

rs7901695, rs7903146 or rs12255372 respectively) (Table 7). However, in the joint analysis of the highly correlated SNP rs7901695/rs7903146 with rs11196205 or rs12255372, the association of

rs7901695 (model A, p = 0.61 and p = 0.3, respectively) or rs7903146 (model A, p = 0.624 and p = 0.322, respectively) with amygdalar volume became non- significant. Similarly, the joint

analysis of rs12255372 with any of the other SNPs (Table 7) was not significant. Therefore, we assume that none of the three SNPs rs7901695, rs7903146 and rs12255372 contributed

independently to the association with amygdalar volume, beyond the effect of the most highly significant SNP rs11196205. Due to a variable levels of linkage disequilibrium (LD) between the

four _TCF7L2_ SNPs, we performed haplotype analysis. Two haplotype blocks were found: 1. rs7901695 and rs7903146 (first block); 2. rs11196205 and rs12255372 (second block). Consistent with

the recessive model, participants with two copies of the first block CT haplotype (rs7901695-C and rs7903146-T, N = 32) or participant with two copies of the second block CT haplotype

(rs11196205-C and rs12255372-T, N = 35) had significantly smaller amygdalar volume compared to participants with other haplotype combinations in the same block (Supplementary Table 2). These

results were essentially identical to the association of rs7903146 and rs12255372 alone, respectively (model A- p = 0.003; model B- p = 0.005). Combining all SNPs, carriers of two copies of

the CTCT haplotype (rs7901695-C, rs7903146-T, rs11196205-C and rs12255372-T, N = 29) had significantly smaller amygdalar volume compared to participants with other haplotypes combinations

(model A- p = 0.013; model B- p = 0.014). Information regarding the haplotype analysis, including haplotypes frequencies, is presented in Supplementary Tables 2 and 3. A posteriori power

estimates (based on the observed regression coefficients) for rs11196205 association with amygdalar volume in our sample (recessive model, minor allele frequency of 0.487, required p = 

0.05), ranged from 94% (adjusting for only age, sex and TICV) to 89% (adjusting also for additional covariates). A posteriori power estimates for the other three SNPs (rs7901695, rs7903146

and rs12255372) association with amygdalar volume (recessive model, minor allele frequency of 0.382–0.403, required p = 0.05), were 77–83% (model A) and 68–78% (model B). Interestingly, we

also found a significant association of rs11196205 with hippocampal and gray matter volume under the recessive genetic model at a nominal significance level (β = −0.141, p = 0.035 and β = 

−0.085, p = 0.044, respectively), but these results became marginal when the second set of covariates was added (model B- β = −0.121, p = 0.064 and β = −0.075, p = 0.072, respectively)

(Table 5). All other associations (amygdalar volume in the additive and dominant models, as well as all models for WMH, hippocampal and gray matter volumes) did not reach the required level

of significance after correction for multiple testing. ASSOCIATION OF _TCF7L2_ SNPS WITH LEFT VERSUS RIGHT AMYGDALAR VOLUME In a secondary analysis we applied similar linear regression for

left and right amygdala separately, in accordance to previous evidence in the literature showing differences between the two sides34. As shown in Table 8, association results of all four

SNPS are stronger (at the significance level achieved) for the left amygdala under recessive model (Model B- rs7901695 β = −0.19, p = 0.005; rs7903146 β = −0.19, p = 0.006; rs11196205 β = 

−0.24, p = 0.0004; and rs12255372 β = −0.21, p = 0.002), while weaker for the right amygdala (Model B- rs7901695 β = −0.18, p = 0.012; rs7903146 β = −0.17, p = 0.018; rs11196205 β = −0.19, p

 = 0.006; and rs12255372 β = −0.16, p = 0.025). Looking at the left amygdala separately, results of conditional (Table 9) and haplotype (Supplementary Table 2) analyses are similar to that

of the total amygdalar volume. DISCUSSION The well-established association of _TCF7L2_ with T2D and the link between T2D and brain imaging changes, have motivated us study the association of

this gene with neuroimaging phenotypes in our sample of elderly T2D Jewish patients. We have found a consistent association of _TCF7L2_ SNPs with amygdalar volume. In the four investigated

SNPs (rs7901695, rs7903146, rs11196205, and rs12255372), carriers of two copies of the T2D risk allele had smaller amygdalar volume, compared to carriers of the non-risk allele (recessive

model), while controlling for sex, age and TICV. Adjusting also for T2D related covariates, BMI, ancestry and blood pressure did not change the results substantially. Further examination of

the left and right amygdala separately, revealed that the association is derived mainly due to the left amygdalar volume (p = 0.0004–0.006) than the right amygdalar volume (p = 0.006–0.025).

On conditional analysis, we found that rs7901695, rs12255372 or rs7903146 SNPs associations with amygdalar volume were not independent of the most highly significant SNP rs11196205, and

therefore only one association signal was detected in region. No associations of hippocampal, gray matter and WMH volumes with _TCF7L2 SNPs_ withstood Bonferroni adjustment for multiple 

testing correction. Several limitations of this study should be considered. Our sample size (N = 191 individuals) is considered small in the context of a genetic association study.

Nevertheless, the sample is unique, since it includes only T2D elderly, a population at risk for cognitive decline and dementia. All participants had clinical (including measures of glycemic

control), neuroimaging and genetic data. Some of the associations survived Bonferroni correction for multiple  testing, indicating robustness of the results and therefore reducing the

likelihood of false positive results. The mere nominal level of association with gray matter and hippocampal volume, which did not withstand the Bonferroni correction, might be due to a

small sample size, and larger size would have been an advantage in terms of statistical power. In addition, the cross-sectional design of the study impedes reaching conclusions of causality.

The longitudinal component of the IDCD is ongoing and may assist in shedding light on functional effect of this association in the future. Previous neuroimaging genetics studies did not

find association of _TCF7L2_ with amygdalar volume. Of particular interest is a recent GWAS meta-analysis study of ~30,000 participants (mostly European origin) conducted by the Enhancing

Neuro Imaging Genetics through Meta-Analysis (ENIGMA) consortium35 (which did not include specific cohorts of T2D patients in particular). No significant associations (additive model, p <

 0.05) were found in this study between amygdalar volume and _TCF7L2_ SNPs rs7901695, rs7903146 and rs12255372. Although rs11196205 was not tested directly in the ENIGMA GWAS, its proxy SNP

rs10885409 (D′ = 1, r2 > 0.95), found by using the Broad institute SNP proxy search (http://archive.broadinstitute.org/mpg/snap/ldsearch.php), was not significantly associated with

amygdalar volume as well. Several explanations for the discrepancy in results are plausible in addition to different genetic model, including that the observed association of _TCF7L2_ with

amygdalar volume is specific to the Jewish population, or alternatively is specific to T2D affected individuals. Our study did not include control participants without T2D, and therefore we

cannot address the generalization of this finding to non-T2D individuals. It is also possible that the association is influenced by older age and potentially not found in younger population

(this sample include individuals aged 65 years and older). Taken together, at the current stage, our findings should be considered as preliminary and caution is required in their 

interpretation. Further studies are required in various populations to validate it. The amygdala, one of the limbic system’s components, has been implicated in several functions - mainly

emotional processing and responses (e.g. fear, anxiety, and aggression), decision-making, associative learning and memory36. Amygdalar aberrant function or structure is common in

neurodevelopmental disorders37. Previous studies in various populations have reported association of variation in several genes with amygdalar volume, including _STMN1_ and _SLC6A4_38,

_CACNA1C_39,40 and the oxytocin receptor _OXTR_41,42. Consistent with our results, previous reports have demonstrated an association between structural brain changes and T2D, e.g. lower

brain volumes and greater brain atrophy in T2D patients24,25,26, including amygdala30. Indeed, greater amygdalar atrophy had been associated with high plasma glucose levels within the normal

range31. _TCF7L2_ is expressed in many brain regions, including the amygdala in mice43 and at a relatively low level in human amygdala (Genotype Tissue expression portal, GTex, Broad

Institute; https://gtexportal.org/home/gene/TCF7L2/). As part of the Wnt/beta-catenin signaling pathway, _TCF7L2_ plays role in the activation of lymphoid enhancer-binding factor 1/T cell

factor (LEF1/TCF) transcription factors complexes. The Wnt/beta-catenin signaling is involved in neuroplasticity, adult neurogenesis and CNS development44,45,46, as well as in

amygdala-dependent learning and long-term memory formation47. Decreased levels of beta‐catenin were found in the amygdala of rats that showed behavioral sensitization to administration of

drugs of abuse48. In humans, polymorphisms in _TCF7L2_ were associated with schizophrenia and bipolar disorder20,21,22. At the behavioral level in animal models, _TCF7L2_ deficient mice

demonstrated altered anxiety like behavior and fear learning49, and this gene mediated cellular and behavioral response to lithium treatment in mice and zebrafish50. Combined, these

evidences implicate a role of _TCF7L2_ in brain function and behavioral phenotypes. To conclude, our results in a sample of T2D elderly demonstrate for the first-time associations of four

_TCF7L2 SNPs_ with amygdalar volume. Confirmation of these results in additional cohorts is required in order to reach more definitive conclusions. METHODS SAMPLE Participants were recruited

from the Israel Diabetes and Cognitive Decline (IDCD) study, a collaboration of the Icahn School of Medicine, Mount Sinai, NY, USA, Sheba Medical Center, Israel, and the Maccabi Health

Services (MHS), Israel. The IDCD study design has been previously described in detail51. Briefly, community-dwelling Israeli elderly individuals with T2D (≥65 years old) were recruited from

the MHS diabetes registry. Criteria for enrolment into the IDCD study were: (1) having T2D (defined as any of the following- (A) HbA1c > 7.25%; (B) Glucose blood levels of 200 mg/dl on

two examinations more than 3 months apart; (C) purchase of diabetic medication twice within 3 months; or (D) diagnosis of T2D (International Classification of Diseases [ICD9] code) by a

general practitioner, internist, endocrinologist, ophthalmologist, or diabetes advisor, supported by a HbA1c > 6.5% or glucose > 125 mg/dl within half a year); (2) normal cognition at

entry to the IDCD study; (3) being free of any neurological (e.g., Parkinson’s disease, stroke), psychiatric (e.g. schizophrenia) or other diseases (e.g., alcohol or drug abuse) that might

affect cognition; (4) having an informant; (5) fluency in Hebrew; (6) living in the area of Tel Aviv. The Diabetes Registry has collected detailed laboratory, medication, and diagnoses

information since 199852. Based on self-report, the IDCD individuals are unrelated to each other (at least at first- and second-degree level). The HbA1c and blood pressure (systolic and

diastolic) values were calculated for each participant as the means of all measurements in the diabetes registry. MRI ACQUISITION A randomly recruited sub-sample of the IDCD cohort underwent

MRI scan, performed at the Diagnostic Imaging Department, Sheba Medical Center using a 3 Tesla scanner (GE, Signa HDxt, v16VO2). High-resolution (1 mm3) images were acquired by using a 3D

inversion recovery prepared fast spoiled gradient-echo (FSPGR) T1-weighted sequence (TR/TE = 7.3/2.7 s, 20° flip angle, TI 450 ms). In addition, a T2-weighted fluid-attenuated inversion

recovery (FLAIR) sequence was acquired with the following parameters: Repetition time/Echo time (TR/TE) 9500/123 ms, axial slices, slice-width/gap 3/0.4 mm, 22 cm FOV, 64 × 64 matrix, 90°

flip-angle. MRI ANALYSIS For volumetric analysis, the voxel based morphometry (VBM53) toolbox, (http://www.fil.ion.ucl.ac.uk/spm/ext/#VBMtools) implemented in Statistical Parametric Mapping

(SPM8) software was used on the T1 weighted anatomical images. This procedure included automated iterative skull stripping, segmentation of the images into gray matter, white matter (WM),

cerebrospinal fluid probability images, and spatial normalization of the gray matter images to a customized gray matter template in standard MNI (Montreal Neurological Institute) space.

Finally, the gray matter maps were smoothed using an 8 mm Gaussian kernel. Gray matter probability maps were thresholded at 0.2 to minimize inclusion of incorrect tissue types. Total

intracranial volume (TICV) was calculated by summing the segmented and thresholded images (TICV = gray matter + white matter + cerebrospinal fluid). Based on our a-priori hypothesis, we used

a region of interest (ROI) approach centered on the amygdala and hippocampus, identified with the ‘Human Automated Anatomical Labelling (AAL) atlas’54 within the Wake Forest University

PickAtlas (http://www.rad.wfubmc.edu/fmri) and extracted using the MarsBaR ROI toolbox55 as implemented in SPM12. All reported volumes are total regional volumes. For WMH quantification we

used the Lesion segmentation toolbox (LST) (implemented in SPM8), following previously described methods32. The default LST settings were used with the exception of κ (k), a value indicating

the threshold for the initial lesion mask. Visual inspection of the probability maps across participants by using various k values, to maximize sensitivity while reducing false positive

results, indicated that a k = 0.15 was the optimal value for our sample images. This procedure generated one binary lesion image per participant from which a total lesion volume (in

milliliters) map was extracted. SNPS SELECTION AND GENOTYPING Four intronic _TCF7L2_ SNPs (rs7901695, rs7903146, rs11196205, and rs12255372) were selected for this study (Table 2), based on

ample evidence of their confirmed association with T2D and related traits4,5. These SNPs were genotyped with the Sequenom MassARRAY system, at the Washington University Human Genetics

Division Genotyping Core, St. Louis, USA. Quality control measures were implemented. STATISTICAL ANALYSIS We employed hierarchical linear regression to study the association of the _TCF7L2_

SNPs with amygdalar, hippocampal, gray matter and WMH volumes, under three genetic models (additive, dominant and recessive – referring to the effect of the T2D risk allele). In the basic

regression model (model A), we controlled for sex, age at IDCD baseline recruitment and TICV (this covariate was included in the models for gray matter, hippocampus and amygdala). In the

second step (model B), we included in the regression model all the covariates from model A, in addition to a set of T2D related characteristics (time in the MHS diabetes registry [an

approximation to T2D duration56], mean HbA1C levels, use of T2D medication [yes/no]), mean body mass index (BMI), and ancestry (Ashkenazi vs. Non-Ashkenazi, based on self-report and land of

birth data). In the third step (model C), we included in the regression model all the covariates from models A and B, in addition to mean systolic and mean diastolic blood pressure. The

analysis was conducted for each SNP and brain region separately. For each brain region, a two-sided p value of 0.0042 (0.05/12) was considered statistically significant following employment

of Bonferroni correction for multiple testing (0.05/[4 SNPs included in the final analysis × 3 genetic models]). For statistical analysis, we used SPSS version 21.0 (SPSS Inc., Chicago, IL,

USA). Hardy–Weinberg calculations, SNPs pairwise correlation and linkage disequilibrium (LD) values were obtained with PLINK (http://pngu.mgh.harvard.edu/purcell/plink)57. For the WMH, we

applied square-root transformation to obtain normal distribution. Power calculation for _TCF7L2_ SNPs association with amygdalar volume was carried by Quanto v1.2.4 software58. To assess a

potential distinct contribution of the four _TCF7L2_ SNPs on amygdalar volume, we performed conditional analysis for each SNP (adjusting for a second SNPs within the regression model, coded

recessively). For haplotype analysis, we used PLINK to determine haplotypes blocks and frequencies. We employed hierarchical linear regression to study the association of the _TCF7L2_

haplotypes with amygdalar volume under recessive model (comparing carriers of two copies of haplotype of interest, to carriers of all other haplotypes combinations), adjusting for

covariates. STUDY APPROVAL AND INFORMED CONSENT All participants provided informed consent, and all experimental protocols were approved by the institutional review boards (IRBs) of all

three collaborating institutions (Icahn School of Medicine, Mount Sinai, NY, USA, Sheba Medical Center, Israel, and MHS, Israel). In addition, all the methods were carried out in accordance

with the relevant guidelines and regulations. DATA AVAILABILITY The datasets generated and analyzed during the current study are available from the corresponding author on reasonable

request. CHANGE HISTORY * _ 05 FEBRUARY 2020 An amendment to this paper has been published and can be accessed via a link at the top of the paper. _ REFERENCES * Ahlqvist, E., Ahluwalia, T.

S. & Groop, L. Genetics of type 2 diabetes. _Clin Chem_ 57, 241–254 (2011). CAS  PubMed  Google Scholar  * Billings, L. K. & Florez, J. C. The genetics of type 2 diabetes: what have

we learned from GWAS? _Ann N Y Acad Sci_ 1212, 59–77 (2010). ADS  CAS  PubMed  PubMed Central  Google Scholar  * Sparso, T. _et al_. Combined analysis of 19 common validated type 2 diabetes

susceptibility gene variants shows moderate discriminative value and no evidence of gene-gene interaction. _Diabetologia_ 52, 1308–1314 (2009). CAS  PubMed  Google Scholar  * Peng, S. _et

al_. TCF7L2 gene polymorphisms and type 2 diabetes risk: a comprehensive and updated meta-analysis involving 121,174 subjects. _Mutagenesis_ 28, 25–37 (2013). CAS  PubMed  Google Scholar  *

Tong, Y. _et al_. Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. _BMC Med

Genet_ 10, 15 (2009). PubMed  PubMed Central  Google Scholar  * Palmer, N. D. _et al_. Resequencing and analysis of variation in the TCF7L2 gene in African Americans suggests that SNP

rs7903146 is the causal diabetes susceptibility variant. _Diabetes_ 60, 662–668 (2011). CAS  PubMed  PubMed Central  Google Scholar  * Ferreira, M. C., da Silva, M. E. R., Fukui, R. T.,

Arruda-Marques, M. D. C. & Dos Santos, R. F.  TCF7L2 correlation in both insulin secretion and postprandial insulin sensitivity. _Diabetol Metab Syndr_ 10, 37 (2018).  * Gjesing, A. P.

_et al._ Carriers of the TCF7L2 rs7903146 TT genotype have elevated levels of plasma glucose, serum proinsulin and plasma gastric inhibitory polypeptide (GIP) during a meal test. 

_Diabetologia_ 54, 103–110 (2011).  CAS  PubMed  Google Scholar  * Ip, W., Chiang, Y. T. & Jin, T. The involvement of the wnt signaling pathway and TCF7L2 in diabetes mellitus: The

current understanding, dispute, and perspective. _Cell Biosci_ 2, 28 (2012). CAS  PubMed  PubMed Central  Google Scholar  * MacDonald, B. T., Tamai, K. & He, X. Wnt/beta-catenin

signaling: components, mechanisms, and diseases. _Dev Cell_ 17, 9–26 (2009). CAS  PubMed  PubMed Central  Google Scholar  * Migliorini, A. & Lickert, H. Beyond association: A functional

role for Tcf7l2 in beta-cell development. _Mol Metab_ 4, 365–366 (2015). CAS  PubMed  PubMed Central  Google Scholar  * Lyssenko, V. _et al_. Mechanisms by which common variants in the

TCF7L2 gene increase risk of type 2 diabetes. _J Clin Invest_ 117, 2155–2163 (2007). CAS  PubMed  PubMed Central  Google Scholar  * Sakhneny, L. _et al_. Pancreatic Pericytes Support

Beta-Cell Function in a Tcf7l2-Dependent Manner. _Diabetes_ (2017). * Chen, X. _et al_. The Diabetes Gene and Wnt Pathway Effector TCF7L2 Regulates Adipocyte Development and Function.

_Diabetes_ (2018). * Lee, S., Lee, C. E., Elias, C. F. & Elmquist, J. K. Expression of the diabetes-associated gene TCF7L2 in adult mouse brain. _J Comp Neurol_ 517, 925–939 (2009).

PubMed  PubMed Central  Google Scholar  * Nazwar, T. A., Glassmann, A. & Schilling, K. Expression and molecular diversity of Tcf7l2 in the developing murine cerebellum and brain. _J

Neurosci Res_ 87, 1532–1546 (2009). CAS  PubMed  Google Scholar  * Nagalski, A. _et al_. Postnatal isoform switch and protein localization of LEF1 and TCF7L2 transcription factors in

cortical, thalamic, and mesencephalic regions of the adult mouse brain. _Brain Struct Funct_ (2012). * Murray, K. D., Choudary, P. V. & Jones, E. G. Nucleus- and cell-specific gene

expression in monkey thalamus. _Proc Natl Acad Sci USA_ 104, 1989–1994 (2007). ADS  CAS  PubMed  Google Scholar  * Prokunina-Olsson, L. & Hall, J. L. Evidence for neuroendocrine function

of a unique splicing form of TCF7L2 in human brain, islets and gut. _Diabetologia_ 53, 712–716 (2010). CAS  PubMed  Google Scholar  * Hansen, T. _et al_. At-risk variant in TCF7L2 for type

II diabetes increases risk of schizophrenia. _Biol Psychiatry_ 70, 59–63 (2011). CAS  PubMed  Google Scholar  * Alkelai, A. _et al_. Association of the type 2 diabetes mellitus

susceptibility gene, TCF7L2, with schizophrenia in an Arab-Israeli family sample. _PLoS One_ 7, e29228 (2012). ADS  CAS  PubMed  PubMed Central  Google Scholar  * Winham, S. J. _et al_.

Genome-wide association study of bipolar disorder accounting for effect of body mass index identifies a new risk allele in TCF7L2. _Mol Psychiatry_ 19, 1010–1016 (2014). CAS  PubMed  Google

Scholar  * Ganmore, I. & Beeri, M. S. Magnitude and Trajectories of Cognitive Dysfunction in Type 2 Diabetes Mellitus. _In: Srikanth V and Arvanitakis Z (eds) Type 2 Diabetes and

Dementia_. _Elsevier pp 29–47_ (2018). * McCrimmon, R. J., Ryan, C. M. & Frier, B. M. Diabetes and cognitive dysfunction. _Lancet_ 379, 2291–2299 (2012). PubMed  Google Scholar  * Li,

W., Risacher, S. L., Huang, E., Saykin, A. J. & Alzheimer’s Disease Neuroimaging, I. Type 2 diabetes mellitus is associated with brain atrophy and hypometabolism in the ADNI cohort.

_Neurology_ 87, 595–600 (2016). CAS  PubMed  PubMed Central  Google Scholar  * Biessels, G. J. & Reijmer, Y. D. Brain changes underlying cognitive dysfunction in diabetes: what can we

learn from MRI? _Diabetes_ 63, 2244–2252 (2014). PubMed  Google Scholar  * Moulton, C. D., Costafreda, S. G., Horton, P., Ismail, K. & Fu, C. H. Meta-analyses of structural regional

cerebral effects in type 1 and type 2 diabetes. _Brain Imaging Behav_ 9, 651–662 (2015). PubMed  Google Scholar  * Chen, Z., Li, L., Sun, J. & Ma, L. Mapping the brain in type II

diabetes: Voxel-based morphometry using DARTEL. _Eur J Radiol_ 81, 1870–1876 (2012). PubMed  Google Scholar  * Moran, C. _et al_. Brain atrophy in type 2 diabetes: regional distribution and

influence on cognition. _Diabetes Care_ 36, 4036–4042 (2013). CAS  PubMed  PubMed Central  Google Scholar  * den Heijer, T. _et al_. Type 2 diabetes and atrophy of medial temporal lobe

structures on brain MRI. _Diabetologia_ 46, 1604–1610 (2003). Google Scholar  * Cherbuin, N., Sachdev, P. & Anstey, K. J. Higher normal fasting plasma glucose is associated with

hippocampal atrophy: The PATH Study. _Neurology_ 79, 1019–1026 (2012). PubMed  Google Scholar  * Livny, A. _et al_. Long-term Variability in Glycemic Control Is Associated With White Matter

Hyperintensities in APOE4 Genotype Carriers With Type 2 Diabetes. _Diabetes Care_ 39, 1056–1059 (2016). CAS  PubMed  PubMed Central  Google Scholar  * Livny, A. _et al_. Haptoglobin 1-1

Genotype Modulates the Association of Glycemic Control With Hippocampal Volume in Elderly Individuals With Type 2 Diabetes. _Diabetes_ 66, 2927–2932 (2017). CAS  PubMed  PubMed Central 

Google Scholar  * Markowitsch, H. J. Differential contribution of right and left amygdala to affective information processing. _Behav Neurol_ 11, 233–244 (1998). PubMed  Google Scholar  *

Hibar, D. P. _et al_. Common genetic variants influence human subcortical brain structures. _Nature_ 520, 224–229 (2015). ADS  CAS  PubMed  PubMed Central  Google Scholar  * Janak, P. H.

& Tye, K. M. From circuits to behaviour in the amygdala. _Nature_ 517, 284–292 (2015). ADS  CAS  PubMed  PubMed Central  Google Scholar  * Schumann, C. M., Bauman, M. D. & Amaral, D.

G. Abnormal structure or function of the amygdala is a common component of neurodevelopmental disorders. _Neuropsychologia_ 49, 745–759 (2011). PubMed  Google Scholar  * Stjepanovic, D.,

Lorenzetti, V., Yucel, M., Hawi, Z. & Bellgrove, M. A. Human amygdala volume is predicted by common DNA variation in the stathmin and serotonin transporter genes. _Transl Psychiatry_ 3,

e283 (2013). CAS  PubMed  PubMed Central  Google Scholar  * Lancaster, T. M., Foley, S., Tansey, K. E., Linden, D. E. & Caseras, X. CACNA1C risk variant is associated with increased

amygdala volume. _Eur Arch Psychiatry Clin Neurosci_ 266, 269–275 (2016). CAS  PubMed  Google Scholar  * Wolf, C. _et al_. CACNA1C genotype explains interindividual differences in amygdala

volume among patients with schizophrenia. _Eur Arch Psychiatry Clin Neurosci_ 264, 93–102 (2014). PubMed  Google Scholar  * Furman, D. J., Chen, M. C. & Gotlib, I. H. Variant in oxytocin

receptor gene is associated with amygdala volume. _Psychoneuroendocrinology_ 36, 891–897 (2011). CAS  PubMed  PubMed Central  Google Scholar  * Wang, J. _et al_. Neural mechanisms of

oxytocin receptor gene mediating anxiety-related temperament. _Brain Struct Funct_ 219, 1543–1554 (2014). CAS  PubMed  Google Scholar  * Weaver, C., Turner, N. & Hall, J. Review of the

neuroanatomic landscape implicated in glucose sensing and regulation of nutrient signaling: immunophenotypic localization of diabetes gene Tcf7l2 in the developing murine brain. _J Chem

Neuroanat_ 45, 1–17 (2012). CAS  PubMed  PubMed Central  Google Scholar  * Backman, M. _et al_. Effects of canonical Wnt signaling on dorso-ventral specification of the mouse telencephalon.

_Dev Biol_ 279, 155–168 (2005). CAS  PubMed  Google Scholar  * Budnik, V. & Salinas, P. C. Wnt signaling during synaptic development and plasticity. _Curr Opin Neurobiol_ 21, 151–159

(2011). CAS  PubMed  PubMed Central  Google Scholar  * Brinkmeier, M. L., Potok, M. A., Davis, S. W. & Camper, S. A. TCF4 deficiency expands ventral diencephalon signaling and increases

induction of pituitary progenitors. _Dev Biol_ 311, 396–407 (2007). CAS  PubMed  PubMed Central  Google Scholar  * Maguschak, K. A. & Ressler, K. J. Wnt signaling in amygdala-dependent

learning and memory. _J Neurosci_ 31, 13057–13067 (2011). CAS  PubMed  PubMed Central  Google Scholar  * Cuesta, S., Severin, M. J., Batuecas, J., Rosso, S. B. & Pacchioni, A. M.

Wnt/beta-catenin pathway in the prefrontal cortex is required for cocaine-induced neuroadaptations. _Addict Biol_ 22, 933–945 (2017). CAS  PubMed  Google Scholar  * Savic, D. _et al_.

Modulation ofTcf7l2 expression alters behavior in mice. _PLoS One_ 6, e26897 (2011). ADS  CAS  PubMed  PubMed Central  Google Scholar  * Misztal, K. _et al_. TCF7L2 mediates the cellular and

behavioral response to chronic lithium treatment in animal models. _Neuropharmacology_ 113, 490–501 (2017). CAS  PubMed  Google Scholar  * Beeri, M. S. _et al_. The Israel Diabetes and

Cognitive Decline (IDCD) study: Design and baseline characteristics. _Alzheimers Dement_ 10, 769–778 (2014). PubMed  PubMed Central  Google Scholar  * Heymann, A. D. _et al_. The

implementation of managed care for diabetes using medical informatics in a large Preferred Provider Organization. _Diabetes Res Clin Pract_ 71, 290–298 (2006). PubMed  Google Scholar  *

Ashburner, J. & Friston, K. J. Voxel-based morphometry–the methods. _Neuroimage_ 11, 805–821 (2000). CAS  PubMed  Google Scholar  * Tzourio-Mazoyer, N. _et al_. Automated anatomical

labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. _Neuroimage_ 15, 273–289 (2002). CAS  PubMed  Google Scholar  * Brett, M.,

Anton, J. L., Valabregue, R. & Poline, J. B. Region of interest analysis using an SPM toolbox [abstract]. Presented at the 8th International Conference on Functional Mapping of the Human

Brain. _Sendai_, _Japan Available on CD-ROM in NeuroImage_, _Vol 16_, _No 2_, _abstract 497_ (2002). * West, R. K. _et al_. The association of duration of type 2 diabetes with cognitive

performance is modulated by long-term glycemic control. _Am J Geriatr Psychiatry_ 22, 1055–1059 (2014). PubMed  PubMed Central  Google Scholar  * Purcell, S. _et al_. PLINK: a tool set for

whole-genome association and population-based linkage analyses. _Am J Hum Genet_ 81, 559–575 (2007). CAS  PubMed  Google Scholar  * Gauderman, W. J. Sample size requirements for association

studies of gene-gene interaction. _Am J Epidemiol_ 155, 478–484 (2002). PubMed  Google Scholar  Download references ACKNOWLEDGEMENTS This research was supported by NIA grants R01 AG034087

and R21 AG043878 for Dr. Beeri and P50 AG05138 for Dr. Mary Sano; the Bader Philanthropies and the Leroy Schecter Foundation, as well as a New Investigator Award in Alzheimer’s Disease from

the American Federation for Aging Research for Dr. Cooper. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Neurology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

Ithamar Ganmore & Shahar Shelly * The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel Ithamar Ganmore, Abigail Livny, Ramit Ravona-Springer, Itzik

Cooper, Shahar Shelly, Michal Schnaider Beeri & Lior Greenbaum * Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel Abigail Livny & Galia

Tsarfaty * Memory clinic, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel Ithamar Ganmore & Ramit Ravona-Springer * Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv,

Israel Ithamar Ganmore, Abigail Livny, Ramit Ravona-Springer, Galia Tsarfaty, Anthony Heymann & Lior Greenbaum * Institute for Genomic Medicine, Columbia University, New York, NY, USA

Anna Alkelai * Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA Shahar Shelly * Maccabi Healthcare Services, Tel Aviv, Israel Anthony Heymann * Department of Psychiatry, Icahn

School of Medicine at Mount Sinai, New York, NY, USA Michal Schnaider Beeri * The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel Lior

Greenbaum Authors * Ithamar Ganmore View author publications You can also search for this author inPubMed Google Scholar * Abigail Livny View author publications You can also search for this

author inPubMed Google Scholar * Ramit Ravona-Springer View author publications You can also search for this author inPubMed Google Scholar * Itzik Cooper View author publications You can

also search for this author inPubMed Google Scholar * Anna Alkelai View author publications You can also search for this author inPubMed Google Scholar * Shahar Shelly View author

publications You can also search for this author inPubMed Google Scholar * Galia Tsarfaty View author publications You can also search for this author inPubMed Google Scholar * Anthony

Heymann View author publications You can also search for this author inPubMed Google Scholar * Michal Schnaider Beeri View author publications You can also search for this author inPubMed 

Google Scholar * Lior Greenbaum View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS I.G. and L.G. researched data, performed statistical

analysis and wrote the manuscript; A.L. performed MRI data acquisition, and participated in analysis; R.R.S. and M.S.B. contributed to research design and reviewed the manuscript; I.C.,

A.A., S.S., G.T. and A.H. reviewed the manuscript and contributed to discussion. CORRESPONDING AUTHOR Correspondence to Ithamar Ganmore. ETHICS DECLARATIONS COMPETING INTERESTS The authors

declare no competing interests. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

SUPPLEMENTARY INFORMATION DATASET 1 RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,

adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons

license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a

credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted

use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT

THIS ARTICLE CITE THIS ARTICLE Ganmore, I., Livny, A., Ravona-Springer, R. _et al._ _TCF7L2_ polymorphisms are associated with amygdalar volume in elderly individuals with Type 2 Diabetes.

_Sci Rep_ 9, 15818 (2019). https://doi.org/10.1038/s41598-019-48899-3 Download citation * Received: 09 August 2018 * Accepted: 08 August 2019 * Published: 01 November 2019 * DOI:

https://doi.org/10.1038/s41598-019-48899-3 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative